AML | Clinical

Phase 2b/3 MO-TRANS Trial of Mocravimod Enrolls First Patients With AML

January 23, 2023

After the FDA cleared an investigational new drug application for mocravimod in April 2022, the first patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant have been enrolled in a phase 2b/3 study of the agent.

More Approaches Are Emerging in TP53-Mutated AML

January 23, 2023

Although the need for novel approaches to treat patients with TP53-mutated acute myeloid leukemia remains urgent, cautious optimism may be in order given recent data from clinical trials and upcoming studies.

FDA Approves Olutasidenib in Relapsed/Refractory AML

December 21, 2022

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.